Dianthus Therapeutics (NASDAQ:DNTH) Sets New 1-Year High Following Analyst Upgrade

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) shares hit a new 52-week high on Tuesday after HC Wainwright raised their price target on the stock from $47.00 to $130.00. HC Wainwright currently has a buy rating on the stock. Dianthus Therapeutics traded as high as $84.86 and last traded at $79.23, with a volume of 4610745 shares trading hands. The stock had previously closed at $65.20.

Other research analysts have also issued research reports about the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. Wedbush raised their price objective on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 11th. Stifel Nicolaus set a $120.00 price objective on Dianthus Therapeutics in a report on Monday. TD Cowen reaffirmed a “buy” rating on shares of Dianthus Therapeutics in a research report on Monday. Finally, Truist Financial increased their target price on Dianthus Therapeutics from $63.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $98.67.

Dianthus Therapeutics News Summary

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: Early “GO” decision in the Phase 3 CAPTIVATE CIDP trial — interim responder analysis met the company’s GO criteria (20 confirmed responders with fewer than 40 Part A completers); company will keep the 300mg S.C. Q2W dose and plans regulator engagement, a material clinical de‑risking event and the primary catalyst for the rally. Dianthus Announces Early GO Decision
• Positive Sentiment: Analyst upgrades/price‑target increases — HC Wainwright raised its target to $130 (buy) and Truist raised its target to $110 (buy). Upgrades increase buy‑side visibility and can amplify momentum after positive trial news. Benzinga
• Neutral Sentiment: Conference call/webcast to discuss interim responder analysis — management hosted a call to provide details, giving investors more color on the result and regulator engagement plans (increases transparency but depends on call tone). Dianthus to Host Conference Call
• Neutral Sentiment: Press and valuation pieces are drawing attention — several articles are re‑evaluating DNTH’s valuation after strong share gains, which can attract momentum traders and long‑term reallocations. Investors.com Yahoo Finance
• Neutral Sentiment: Short‑interest data shows 0 shares (report appears to be an artifact) — this reported figure is not meaningful and should not be interpreted as bearish evidence.
• Negative Sentiment: Filed a proposed $400M underwritten public offering (plus up to $60M option) — large equity raises typically dilute existing holders; while proceeds can fund development and commercialization, the market often treats such filings as near‑term negative. Dianthus Announces Proposed $400M Offering
• Negative Sentiment: Q4 earnings miss — reported loss of $1.43/share vs. consensus of ~$0.98 and negative margins/ROE; weaker results can temper enthusiasm and help explain the need for a capital raise. Zacks: Q4 Loss, Miss

Institutional Investors Weigh In On Dianthus Therapeutics

A number of large investors have recently bought and sold shares of DNTH. Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics in the 2nd quarter valued at approximately $27,000. Parkside Financial Bank & Trust boosted its position in shares of Dianthus Therapeutics by 131.7% during the 3rd quarter. Parkside Financial Bank & Trust now owns 950 shares of the company’s stock worth $37,000 after acquiring an additional 540 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Dianthus Therapeutics during the 4th quarter worth approximately $40,000. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics in the third quarter valued at approximately $64,000. Finally, Tower Research Capital LLC TRC raised its position in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock valued at $80,000 after purchasing an additional 3,317 shares in the last quarter. 47.53% of the stock is currently owned by institutional investors and hedge funds.

Dianthus Therapeutics Price Performance

The firm’s 50-day simple moving average is $49.17 and its 200 day simple moving average is $41.17. The firm has a market capitalization of $3.42 billion, a price-to-earnings ratio of -22.77 and a beta of 1.56.

Dianthus Therapeutics (NASDAQ:DNTH) last issued its earnings results on Monday, March 9th. The company reported ($1.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.46). Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. The business had revenue of $0.57 million during the quarter, compared to analyst estimates of $0.40 million. As a group, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.